Morgan Stanley raised the firm’s price target on Moderna (MRNA) to $32 from $31 and keeps an Equal Weight rating on the shares. Ahead of Q3 earnings, the firm adjusted models for IQVIA trends as well as intra-quarter updates, the analyst tells investors in a preview for the biopharma group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA: